MET: A promising anticancer therapeutic target

Nature Reviews Clinical Oncology

Volumn 9, Issue 6, 2012, Pages 314-326

  Peters, Solange ^a   Adjei, Alex A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; DOCETAXEL; ERLOTINIB; FICLATUZUMAB; FLUOROURACIL; FOLIC ACID; FORETINIB; GANITUMAB; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY; MOTESANIB; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PLATINUM COMPLEX; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; TAK 701; TEMOZOLOMIDE; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BLEEDING; BLOOD TOXICITY; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GALLBLADDER DISEASE; GENE MUTATION; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPOKALEMIA; ILEUS; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MIXED TUMOR; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PAPILLARY CARCINOMA; PAPILLARY RENAL CARCINOMA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PLEURA EFFUSION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; PRURITUS; REVIEW; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMACH TUMOR; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TRIPLE NEGATIVE BREAST CANCER; URINARY TRACT INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84861733799     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.71     Document Type: Review

References (190)

1. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (2003). (Pubitemid 37493640)
2. Gherardi, E., Birchmeier, W., Birchmeier, C. & Vande Woude, G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012).
3. Di Renzo, M. F. et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1, 147-154 (1995).
4. Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 51, 172-178 (2001). (Pubitemid 32337066)
5. Fujita, S. & Sugano, K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J. Clin. Oncol. 27, 378-383 (1997). (Pubitemid 127519258)
6. Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386-396 (1995).
7. Inoue, T. et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 95, 803-808 (2004). (Pubitemid 39545586)
8. Jin, L. et al. Expression of scatter factor and cmet receptor in benign and malignant breast tissue. Cancer 79, 749-760 (1997). (Pubitemid 27076341)
9. Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-1417 (1998). (Pubitemid 28411378)
10. Smolen, G. A. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA665752. Proc. Natl Acad. Sci. USA 103, 2316-2321 (2006). (Pubitemid 43271667)
11. Wu, F. et al. The clinical value of hepatocyte growth factor and its receptor-cmet for liver cancer patients with hepatectomy. Dig. Liver Dis. 38, 490-497 (2006). (Pubitemid 44356232)
12. Ferracini, R. et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-749 (1995).
13. Webb, C. P. et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60, 342-349 (2000). (Pubitemid 30070761)
14. Jin, J. et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 22, 2568-2572 (2011).
15. Wu, Z S. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer 117, 2842-2852 (2011).
16. Bertotti, A. et al. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin. Cancer Res. 16, 3933-3943 (2010).
17. Comoglio, P. M., Giordano, S. & Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516 (2008). (Pubitemid 351767118)
18. Knudsen, B. S. & Vande Woude, G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18, 87-96 (2008). (Pubitemid 351694452)
19. Burgess, T. et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66, 1721-1729 (2006). (Pubitemid 43259957)
20. Kim, K. J. et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12, 1292-1298 (2006). (Pubitemid 43342521)
21. Patnaik, A. et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a2525 (2010).
22. Tan, E. et al. Phase Ib study of ficlatuzumab (formerly AV299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC [abstract]. J. Clin. Oncol. 29 (Suppl.), a7571 (2011).
23. Mok, T. et al. Randomized phase II study of ficlatuzumab (formerly AV299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS213 (2011).
24. Giordano, S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr. Opin. Mol. Ther. 11, 448-455 (2009).
25. Buchanan, I. M. et al. Radiosensitization of glioma cells by modulation of Met signaling with the hepatocyte growth factor neutralizing antibody, AMG102. J. Cell. Mol. Med. 15, 1999-2006 (2011).
26. Jun, H. T. et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U87 MG cells and xenografts. Clin. Cancer Res. 13, 6735-6742 (2007). (Pubitemid 350206811)
27. Gordon, M. S. et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin. Cancer Res. 16, 699-710 (2010).
28. Rosen, P. J. et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin. Cancer Res. 16, 2677-2687 (2010).
29. Wen, P. Y. et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncology 13, 437-446 (2011).
30. Eng, C. et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses [abstract]. J. Clin. Oncol. 29 (Suppl.), a3500 (2011).
31. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00422019 (2011).
32. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01113398 (2011).
33. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01233687 (2012).
34. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00791154 (2011).
35. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00719550 (2011).
36. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01443065 (2011).
37. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01105390 (2011).
38. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00770848 (2011).
39. Hori, A. et al. Monotherapeutic and combination antitumor activities of TAK701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer [abstract]. Proc. Am. Assoc. Cancer Res. a1244 (2009).
40. Okamoto, W. et al. TAK701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol. Cancer Ther. 9, 2785-2792 (2010).
41. Jones, S. F. et al. Safety, tolerability, and pharmacokinetics of TAK701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study [abstract]. J. Clin. Oncol. 28 (Suppl.), a3081 (2010).
42. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00831896 (2011).
43. Martens, T. et al. A novel one-armed anticMet antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12, 6144-6152 (2006). (Pubitemid 44703780)
44. Xu, H. et al. Dual blockade of EGFR and cMet abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin. Cancer Res. 17, 4425-4438 (2011).
45. Jin, H. et al. MetMAb, the one-armed 5D5 anticMet antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368 (2008).
46. Spigel, D. R. et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J. Clin. Oncol. 29 (Suppl.), a7505 (2011).
47. Benedettini, E. et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 177, 415-423 (2010).
48. Krumbach, R. et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47, 1231-1243 (2011).
49. Stabile, L. P. et al. Targeting of both the cMet and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers (Basel) 2, 2153-2170 (2010).
50. McDermott, U., Pusapati, R. V., Christensen, J. G., Gray, N. S. & Settleman, J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 70, 1625-1634 (2010).
51. Hammerman, P. S., Janne, P. A. & Johnson, B. E. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 15, 7502-7509 (2009).
52. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
53. Yu, W. et al. Exploratory biomarker analyses from OAM4558g: a placebo-controlled phase II study of erlotinib ± MetMAb in patients with advanced non-small-cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a7529 (2011).
54. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01456325 (2012).
55. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01186991 (2012).
56. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01418222 (2012).
57. Merchant, M. et al. Proof of concept of immuno-PET molecular imaging of met using 76Br- and 89Zr-labeled MetMAb [abstract]. J. Clin. Oncol. 29 (Suppl.), a10632 (2011).
58. Schiering, N. et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor cMet and its complex with the microbial alkaloid K252a. Proc. Natl Acad. Sci. USA 100, 12654-12659 (2003). (Pubitemid 37339954)
59. Bladt, F. et al. Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the cMet kinase in phase I clinical trials [abstract]. Proc. Am. Assoc. Cancer Res. a3622 (2010).
60. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01014936 (2012).
61. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01110083 (2011).
62. Falchook G. S. et al. Phase I dose-escalation study of the oral selective c-Met inhibitor EMD 1204831 in patients with advanced solid tumours [abstract]. Eur. J. Cancer 47 (Suppl.), 158 (2011).
63. Liu, X. et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER3. Clin. Cancer Res. 17, 7127-7138 (2011).
64. Donehower, R. C. et al. A phase I dose-escalation study of INCB028060, an inhibitor of cMET receptor tyrosine kinase, in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 29 (Suppl.), a3091 (2011).
65. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01072266 (2012).
66. Eathiraj, S. et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J. Biol. Chem. 286, 20666-20676 (2011).
67. Munshi, N. et al. ARQ 197, a novel and selective inhibitor of the human cMet receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9, 1544-1553 (2010).
68. Jänne, P. MET inhibitors [abstract 299]. Eur. J. Cancer 47 (Suppl.), 68 (2011).
69. Yap, T. A. et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 29, 1271-1279 (2011).
70. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00874042 (2011).
71. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01075048 (2012).
72. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00827177 (2011).
73. Feldman, D. R. et al. A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs) [abstract]. J. Clin. Oncol. 29 (Suppl.), a4638 (2011).
74. Sequist, L. V. et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 29, 3307-3315 (2011).
75. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01244191 (2012).
76. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01395758 (2012).
77. Adjei, A. A., Schwartz, B. & Garmey, E. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 16, 788-799 (2011).
78. Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of cMet and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507-3516 (2010).
79. Qian, F. et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009-8016 (2009).
80. You, W. K. et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758-4768 (2011).
81. Srinivasan, R. et al. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC) [abstract]. J. Clin. Oncol. 27 (Suppl.), a5103 (2009).
82. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00725712 (2011).
83. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00725764 (2010).
84. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00920192 (2009).
85. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00726323 (2012).
86. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01147484 (2012).
87. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01068587 (2012).
88. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01138384 (2011).
89. Sennino, B. et al. Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184 [abstract]. Mol. Cancer Ther. 8 (Suppl. 12), A13 (2009).
90. Jänne, P. A., Wax, M., Leach, J., Shankar, G. & Engelman, J. Targeting MET with XL184 to reverse EGFR tyrosine kinase in- hibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical design [abstract]. Eur. J. Cancer 6, a552 (2008).
91. Kurzrock, R. et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666 (2011).
92. Gordon, M. S. et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 29 (Suppl.), a3010 (2011).
93. Hussain, M. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial [abstract]. J. Clin. Oncol. 29 (Suppl.), a4516 (2011).
94. Buckanovich R. J. et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [abstract]. J. Clin. Oncol. 29 (Suppl.), a5008 (2011).
95. Wakelee, H. et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a3017 (2010).
96. Wen, P. et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a2006 (2010).
97. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00704730 (2011).
98. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01428219 (2012).
99. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01441947 (2012).
100. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01466036 (2011).
101. Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
102. Soda, M. et al. A mouse model for EML4-ALK-positive lung cancer. Proc. Natl Acad. Sci. USA 105, 19893-19897 (2008).
103. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med 363, 1693-1703 (2010).
104. Ou, S. H. et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
105. Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007). (Pubitemid 46815090)
106. Robert, F. et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 3234-3243 (2001). (Pubitemid 32591441)
107. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00651365 (2012).
108. Buchanan, S. G. et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther. 8, 3181-3190 (2009).
109. Ellis, P. M. & Al-Saleh, K. Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions. Crit. Rev. Oncol. Hematol. http://dx.doi.org/10.1016/j.critrevonc.2012.02.004.
110. Lai, A. Z., Abella, J. V. & Park, M. Crosstalk in Met receptor oncogenesis. Trends Cell. Biol. 19, 542-551 (2009).
111. Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699-702 (1995).
112. Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705 (1995).
113. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the cmet receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771 (1995).
114. Maina, F. & Klein, R. Hepatocyte growth factor, a versatile signal for developing neurons. Nat. Neurosci. 2, 213-217 (1999). (Pubitemid 30491290)
115. Matsumoto, K. & Nakamura, T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 59, 2023-2038 (2001). (Pubitemid 32467594)
116. Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60-66 (1997).
117. Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y. & Matsuda, H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511-1519 (2000). (Pubitemid 32038589)
118. Rabkin, R. et al. Hepatocyte growth factor receptor in acute tubular necrosis. J. Am. Soc. Nephrol. 12, 531-540 (2001). (Pubitemid 32180022)
119. Trusolino, L., Bertotti, A. & Comoglio, P. M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848 (2010).
120. Onimaru, Y. et al. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and cMet. Int. J. Oncol. 33, 697-703 (2008).
121. Verstovsek, S. et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15, 1165-1170 (2001). (Pubitemid 32776439)
122. Jucker, M. et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leukemia Res. 18, 7-16 (1994).
123. Wang, P. et al. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology 69, 780-784 (2007). (Pubitemid 46574944)
124. Miyata, Y., Sagara, Y., Kanda, S., Hayashi, T. & Kanetake, H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and 7 and Ecadherin. Hum. Pathol. 40, 496-504 (2009).
125. Rosen, E. M. et al. Scatter factor expression and regulation in human glial tumors. Int. J. Cancer 67, 248-255 (1996). (Pubitemid 26274157)
126. Koochekpour, S. et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 57, 5391-5398 (1997). (Pubitemid 27516379)
127. Moriyama, T., Kataoka, H., Tsubouchi, H. & Koono, M. Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro. FEBS Lett. 372, 78-82 (1995).
128. Nabeshima, K. et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31, 436-443 (1997). (Pubitemid 27505360)
129. Kong, D. S. et al. Prognostic significance of c-Met expression in glioblastomas. Cancer 115, 140-148 (2009).
130. Moon, Y. W. et al. Missense mutation of the MET gene detected in human glioma. Mod. Pathol. 13, 973-977 (2000).
131. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007).
132. Ma, J. et al. Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J. Clin. Invest. 119, 478-491 (2009).
133. Yamashita, J. et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54, 1630-1633 (1994). (Pubitemid 24116158)
134. Tuck, A. B., Park, M., Sterns, E. E., Boag, A. & Elliott, B. E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am. J. Pathol. 148, 225-232 (1996). (Pubitemid 26022451)
135. Camp, R. L., Rimm, E. B. & Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-2265 (1999). (Pubitemid 30010366)
136. Graveel, C. R. et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc. Natl Acad. Sci. USA 106, 12909-12914 (2009).
137. Walker, F. et al. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin. Cancer Res. 9, 273-284 (2003). (Pubitemid 36109744)
138. Baykal, C., Ayhan, A., Al, A. & Yuce, K. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol. Oncol. 88, 123-129 (2003). (Pubitemid 36263369)
139. Aishima, S. I., Taguchi, K. I., Sugimachi, K., Shimada, M. & Tsuneyoshi, M. c-ErbB2 and cMet expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40, 269-278 (2002). (Pubitemid 34227118)
140. Zhelyazkova, A. G., Tonchev, A. B., Kolova, P., Ivanova, L. & Gercheva, L. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia. Scand. J. Clin. Lab. Invest. 68, 492-500 (2008).
141. Kammula, U. S. et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-228 (2007). (Pubitemid 46330555)
142. Zeng, Z. S. et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-269 (2008).
143. Samuelson, E., Levan, K., Adamovic, T., Levan, G. & Horvath, G. Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 181, 25-30 (2008). (Pubitemid 351192040)
144. Wu, C. W. et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol. Rep. 5, 817-822 (1998).
145. Kuniyasu, H. et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 189, 227-232 (1992). (Pubitemid 23030031)
146. Nakajima, M. et al. The prognostic significance of amplification and overexpression of c-met and cerb B2 in human gastric carcinomas. Cancer 85, 1894-1902 (1999). (Pubitemid 29202761)
147. Houldsworth, J., Cordon-Cardo, C., Ladanyi, M., Kelsen, D. P. & Chaganti, R. S. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res. 50, 6417-6422 (1990). (Pubitemid 20323708)
148. Uchida, D. et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int. J. Cancer 93, 489-496 (2001). (Pubitemid 32701407)
149. Lo Muzio, L. et al. Effect of cMet expression on survival in head and neck squamous cell carcinoma. Tumour Biol. 27, 115-121 (2006).
150. Di Renzo, M. F. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19, 1547-1555 (2000). (Pubitemid 30175676)
151. Betsunoh, H. et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-498 (2007). (Pubitemid 46562738)
152. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73 (1997). (Pubitemid 27198158)
153. Schmidt, L. et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18, 2343-2350 (1999). (Pubitemid 29192711)
154. Daveau, M. et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinogen. 36, 130-141 (2003). (Pubitemid 36314790)
155. Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-metproto oncogene, in hepatocellular carcinoma. Hepatology 25, 619-623 (1997). (Pubitemid 27106443)
156. Park, W. S. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59, 307-310 (1999). (Pubitemid 29048858)
157. Etto, L. et al. Clinical correlations and prognostic relevance of HGF, VEGF and FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk. Lymphoma 49, 257-264 (2008). (Pubitemid 351193917)
158. Teofili, L. et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97, 1063-1069 (2001). (Pubitemid 32154294)
159. Tjin, E. P. et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 107, 760-768 (2006). (Pubitemid 43076403)
160. Tong, C. Y. et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J. Neurosurg. 100, 187-193 (2004). (Pubitemid 38141346)
161. Topcu-Yilmaz, P., Kiratli, H., Saglam, A., Soylemezoglu, F. & Hascelik, G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20, 126-32 (2010).
162. Puri, N. et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin. Cancer Res. 13, 2246-2253 (2007). (Pubitemid 46649894)
163. Tolnay, E. et al. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J. Cancer Res. Clin. Oncol. 124, 291-296 (1998). (Pubitemid 28332909)
164. Harvey, P. et al. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J. Pathol. 180, 389-394 (1996). (Pubitemid 27014076)
165. Thirkettle, I., Harvey, P., Hasleton, P. S., Ball, R. Y. & Warn, R. M. Immunoreactivity for cadherins, HGF/SF, Met, and erbB2 in pleural malignant mesotheliomas. Histopathology 36, 522-528 (2000). (Pubitemid 30348777)
166. Jagadeeswaran, R. et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66, 352-361 (2006). (Pubitemid 43166042)
167. Seidel, C. et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91, 806-812 (1998). (Pubitemid 28078282)
168. Seidel, C., Borset, M., Hjorth-Hansen, H., Sundan, A. & Waage, A. Role of hepatocyte growth factor and its receptor cmet in multiple myeloma. Med. Oncol. 15, 145-153 (1998). (Pubitemid 28496882)
169. Borset, M., Hjorth-Hansen, H., Seidel, C., Sundan, A. & Waage, A. Hepatocyte growth factor and its receptor cmet in multiple myeloma. Blood 88, 3998-4004 (1996). (Pubitemid 26383124)
170. Borset, M. et al. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J. Biol. Chem. 271, 24655-24661 (1996). (Pubitemid 26333208)
171. Nakamura, Y. et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 98, 1006-1013 (2007). (Pubitemid 46865384)
172. Ichimura, E., Maeshima, A., Nakajima, T. & Nakamura, T. Expression of cmet/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J. Cancer Res. 87, 1063-1069 (1996). (Pubitemid 26392044)
173. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). (Pubitemid 46799492)
174. Go, H. et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol. 5, 305-313 (2010).
175. Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
176. Cappuzzo, F. et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27, 1667-1674 (2009).
177. Zhao, X. et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65, 5561-5570 (2005). (Pubitemid 40911156)
178. Kong-Beltran, M. et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283-289 (2006). (Pubitemid 43166034)
179. Miller, C. T. et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25, 409-18 (2006). (Pubitemid 43117626)
180. Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol. Int. 48, 757-762 (1998). (Pubitemid 28455692)
181. Baykal, C. et al. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int. J. Gynecol. Cancer 14, 152-156 (2004). (Pubitemid 38280638)
182. Sawada, K. et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67, 1670-1679 (2007). (Pubitemid 46383393)
183. Tanyi, J., Tory, K., Rigó, J. Jr, Nagy, B. & Papp, Z. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas.*. Path. Oncol. Res. 5, 187-191 (1999). (Pubitemid 29510771)
184. Humphrey, P. A. et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin. Genitourin. Cancer 4, 269-274 (2006). (Pubitemid 43779884)
185. Pisters, L. L. et al. cmet proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154, 293-298 (1995).
186. Ide, T. et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 14, 2600-2607 (2007). (Pubitemid 47389573)
187. Ferracini, R. et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12, 1697-1705 (1996). (Pubitemid 26146294)
188. Ma, P. C. et al. cMET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63, 6272-6281 (2003). (Pubitemid 37255174)
189. Papotti, M. et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr. Pathol. 11, 19-30 (2000). (Pubitemid 30307941)
190. Wasenius, V. M. et al. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am. J. Surg. Pathol. 29, 544-549 (2005).